Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oropharyngeal Neoplasms | 35 | 2025 | 268 | 8.390 |
Why?
|
| Papillomavirus Infections | 37 | 2025 | 385 | 8.200 |
Why?
|
| Carcinoma, Squamous Cell | 30 | 2024 | 767 | 3.050 |
Why?
|
| Human papillomavirus 16 | 18 | 2025 | 97 | 3.050 |
Why?
|
| Papillomaviridae | 18 | 2023 | 183 | 2.350 |
Why?
|
| Head and Neck Neoplasms | 18 | 2025 | 622 | 2.170 |
Why?
|
| Alphapapillomavirus | 5 | 2022 | 48 | 1.870 |
Why?
|
| DNA, Viral | 6 | 2025 | 487 | 1.660 |
Why?
|
| Mouth Neoplasms | 8 | 2025 | 97 | 1.520 |
Why?
|
| Early Detection of Cancer | 6 | 2025 | 414 | 1.420 |
Why?
|
| Antibodies, Viral | 6 | 2025 | 1203 | 1.410 |
Why?
|
| Oncogene Proteins, Viral | 4 | 2025 | 63 | 1.250 |
Why?
|
| Papillomavirus Vaccines | 5 | 2022 | 106 | 1.180 |
Why?
|
| Anus Neoplasms | 3 | 2022 | 41 | 1.060 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2022 | 261 | 1.020 |
Why?
|
| Smoking | 11 | 2023 | 940 | 0.910 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 39 | 0.880 |
Why?
|
| Sexual Behavior | 4 | 2018 | 250 | 0.820 |
Why?
|
| Mouth Diseases | 1 | 2023 | 15 | 0.810 |
Why?
|
| Alcohol Drinking | 6 | 2016 | 355 | 0.700 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 36 | 0.700 |
Why?
|
| Middle Aged | 46 | 2025 | 28998 | 0.660 |
Why?
|
| Health Care Costs | 3 | 2020 | 414 | 0.620 |
Why?
|
| Biomarkers, Tumor | 4 | 2025 | 1659 | 0.610 |
Why?
|
| Condylomata Acuminata | 1 | 2018 | 15 | 0.590 |
Why?
|
| Case-Control Studies | 17 | 2023 | 3416 | 0.570 |
Why?
|
| Microbiota | 1 | 2023 | 434 | 0.550 |
Why?
|
| Male | 49 | 2025 | 64967 | 0.550 |
Why?
|
| Mouth | 1 | 2018 | 67 | 0.540 |
Why?
|
| Cancer Survivors | 1 | 2020 | 249 | 0.530 |
Why?
|
| Humans | 66 | 2025 | 132089 | 0.470 |
Why?
|
| Vaccination | 2 | 2018 | 1018 | 0.420 |
Why?
|
| Prognosis | 13 | 2024 | 5014 | 0.420 |
Why?
|
| Neoplasm Staging | 8 | 2016 | 1362 | 0.410 |
Why?
|
| Female | 49 | 2024 | 70695 | 0.410 |
Why?
|
| Aged | 30 | 2024 | 21438 | 0.380 |
Why?
|
| Laryngeal Neoplasms | 3 | 2020 | 91 | 0.350 |
Why?
|
| Prospective Studies | 7 | 2024 | 6572 | 0.350 |
Why?
|
| Prevalence | 8 | 2023 | 2658 | 0.330 |
Why?
|
| Sex Distribution | 5 | 2019 | 328 | 0.310 |
Why?
|
| Age Distribution | 5 | 2018 | 438 | 0.310 |
Why?
|
| Risk Factors | 18 | 2023 | 10946 | 0.300 |
Why?
|
| Mass Screening | 3 | 2025 | 830 | 0.290 |
Why?
|
| Texas | 8 | 2021 | 3629 | 0.280 |
Why?
|
| Insurance, Health | 2 | 2019 | 144 | 0.280 |
Why?
|
| Medicaid | 2 | 2019 | 251 | 0.250 |
Why?
|
| Reference Values | 5 | 2017 | 707 | 0.250 |
Why?
|
| Incidence | 9 | 2020 | 3379 | 0.250 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 468 | 0.240 |
Why?
|
| Logistic Models | 4 | 2017 | 1839 | 0.230 |
Why?
|
| Adult | 23 | 2024 | 31575 | 0.220 |
Why?
|
| Age Factors | 3 | 2020 | 2916 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 5 | 2019 | 1548 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 576 | 0.220 |
Why?
|
| Cohort Studies | 7 | 2017 | 5168 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1500 | 0.210 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2018 | 133 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2022 | 3351 | 0.210 |
Why?
|
| Smokers | 2 | 2020 | 44 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 5416 | 0.200 |
Why?
|
| Retrospective Studies | 10 | 2022 | 17416 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 822 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 1132 | 0.200 |
Why?
|
| Anus Diseases | 1 | 2022 | 14 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2022 | 2849 | 0.200 |
Why?
|
| Vulvar Neoplasms | 1 | 2022 | 21 | 0.190 |
Why?
|
| Cotinine | 3 | 2008 | 24 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2024 | 1460 | 0.190 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 74 | 0.190 |
Why?
|
| Polymorphism, Genetic | 5 | 2016 | 803 | 0.180 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 394 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1305 | 0.180 |
Why?
|
| Mouthwashes | 1 | 2021 | 11 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 2 | 2013 | 149 | 0.170 |
Why?
|
| Pharyngeal Neoplasms | 3 | 2008 | 22 | 0.170 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 30 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 3766 | 0.170 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2020 | 19 | 0.160 |
Why?
|
| Sex Factors | 3 | 2018 | 1355 | 0.160 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 237 | 0.160 |
Why?
|
| Smoking Cessation | 2 | 2020 | 191 | 0.160 |
Why?
|
| MicroRNAs | 2 | 2018 | 917 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 111 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2020 | 72 | 0.160 |
Why?
|
| Direct Service Costs | 1 | 2019 | 12 | 0.160 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 3 | 0.150 |
Why?
|
| DNA-Binding Proteins | 4 | 2015 | 1977 | 0.150 |
Why?
|
| Capsid Proteins | 2 | 2018 | 194 | 0.150 |
Why?
|
| Oropharynx | 2 | 2013 | 36 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2020 | 311 | 0.150 |
Why?
|
| United States | 7 | 2020 | 11667 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 114 | 0.150 |
Why?
|
| Anal Canal | 1 | 2019 | 82 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 333 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 46 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2003 | 812 | 0.140 |
Why?
|
| Cause of Death | 1 | 2020 | 510 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2017 | 3739 | 0.140 |
Why?
|
| Odds Ratio | 4 | 2016 | 1254 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2024 | 1573 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2024 | 1697 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 573 | 0.130 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1997 | 19 | 0.130 |
Why?
|
| Alcohols | 1 | 1997 | 17 | 0.130 |
Why?
|
| Lymphocytes | 3 | 2016 | 362 | 0.130 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1997 | 128 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 235 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 713 | 0.130 |
Why?
|
| Genes, p16 | 1 | 2016 | 12 | 0.120 |
Why?
|
| Fungal Proteins | 1 | 1997 | 135 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 291 | 0.120 |
Why?
|
| Recombinational DNA Repair | 1 | 2016 | 18 | 0.120 |
Why?
|
| Young Adult | 4 | 2020 | 9958 | 0.120 |
Why?
|
| DNA Repair | 3 | 2005 | 565 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2018 | 491 | 0.120 |
Why?
|
| Genotype | 8 | 2022 | 2697 | 0.120 |
Why?
|
| RNA Helicases | 1 | 2015 | 69 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 20560 | 0.110 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 36 | 0.110 |
Why?
|
| Apoptosis | 2 | 2016 | 1892 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 301 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1997 | 416 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1694 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 95 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2140 | 0.100 |
Why?
|
| Extremities | 1 | 2013 | 82 | 0.100 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 45 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 54 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 32 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 134 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 959 | 0.090 |
Why?
|
| Survival Rate | 3 | 2024 | 2194 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 902 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2010 | 277 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 308 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 241 | 0.090 |
Why?
|
| Sarcoma | 1 | 2013 | 207 | 0.090 |
Why?
|
| Biomarkers | 1 | 2020 | 3407 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2023 | 1444 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6448 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 83 | 0.080 |
Why?
|
| Medical History Taking | 1 | 2010 | 114 | 0.080 |
Why?
|
| Binding Sites | 3 | 2018 | 1256 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 139 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 806 | 0.070 |
Why?
|
| Disease Progression | 1 | 2015 | 2225 | 0.070 |
Why?
|
| Codon | 1 | 2008 | 98 | 0.070 |
Why?
|
| Dronabinol | 1 | 2008 | 31 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 52 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2008 | 144 | 0.070 |
Why?
|
| Carcinogens | 1 | 2008 | 127 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 89 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2008 | 131 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 13034 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2008 | 189 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2020 | 223 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2169 | 0.060 |
Why?
|
| Gastrostomy | 1 | 2005 | 92 | 0.060 |
Why?
|
| G2 Phase | 1 | 2004 | 42 | 0.050 |
Why?
|
| Gamma Rays | 1 | 2004 | 42 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 339 | 0.050 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2004 | 61 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1828 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2003 | 21 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 763 | 0.050 |
Why?
|
| Registries | 1 | 2010 | 1581 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 442 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2674 | 0.050 |
Why?
|
| State Medicine | 1 | 2022 | 21 | 0.050 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Endonucleases | 1 | 2002 | 50 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 338 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 119 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 250 | 0.040 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2001 | 22 | 0.040 |
Why?
|
| Risk | 1 | 2003 | 761 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 314 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2002 | 239 | 0.040 |
Why?
|
| Vagina | 1 | 2022 | 204 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2020 | 14 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 7104 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 824 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1439 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 46 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 141 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 313 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 285 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 220 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 1473 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 240 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1997 | 88 | 0.030 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2016 | 17 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 1035 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1997 | 158 | 0.030 |
Why?
|
| Glycerol | 1 | 1997 | 82 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 74 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1997 | 301 | 0.030 |
Why?
|
| Viral Core Proteins | 1 | 2016 | 23 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 13 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 347 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1960 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 1336 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 166 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 1278 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2002 | 1580 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1229 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 1129 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2016 | 141 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 875 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 791 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 601 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 3011 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2016 | 389 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 540 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1347 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 167 | 0.030 |
Why?
|
| Genome | 1 | 2016 | 504 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 170 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1284 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2002 | 2493 | 0.020 |
Why?
|
| Base Sequence | 1 | 1997 | 2899 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 392 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1294 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 3770 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2010 | 15 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2161 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3037 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1163 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3681 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2322 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 135 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 140 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 737 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1826 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 14749 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2002 | 19 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 406 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 805 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 70 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 295 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1686 | 0.010 |
Why?
|
| Child | 1 | 2019 | 25786 | 0.010 |
Why?
|
| Alcoholism | 1 | 2001 | 250 | 0.010 |
Why?
|
| Comorbidity | 1 | 2001 | 1611 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 4003 | 0.010 |
Why?
|